PreludeDx

Laguna Hills, United States Founded: 2009 • Age: 17 yrs
Risk assessment tests for early-stage breast cancer are provided.
Request Access

About PreludeDx

PreludeDx is a company based in Laguna Hills (United States) founded in 2009.. PreludeDx has raised $51.65 million across 7 funding rounds from investors including GenesisCare and Evidity Health Capital. The company has 33 employees as of December 31, 2021. PreludeDx offers products and services including DCISionRT. PreludeDx operates in a competitive market with competitors including Raysearch laboratories, Miltel, OncoStem, Inbiomotion and POC Medical Systems, among others.

  • Headquarter Laguna Hills, United States
  • Employees 33 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Prelude Corporation
Operational Areas
Healthcare → Health Technology & Digital Health
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $51.65 M (USD)

    in 7 rounds

  • Latest Funding Round
    $5 M (USD), Series B

    Oct 30, 2025

  • Investors
    GenesisCare

    & 1 more

  • Employee Count
    33

    as on Dec 31, 2021

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of PreludeDx

PreludeDx offers a comprehensive portfolio of products and services, including DCISionRT. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Predicts radiation benefit and recurrence risk for DCIS patients.

People of PreludeDx
Headcount 10-50
Employee Profiles 25
Board Members and Advisors 4
Employee Profiles
People
Lindsey Fields
Conference And Events Manager
People
Karuna Mittal
Senior Director of Research & Development
People
Andrew Wade
CFO
People
Andrew Sundberg
VP, Global Sales

Unlock access to complete

Board Members and Advisors
people
Olav Bergheim
Chairman
people
Gerrit Adams
Board Member
people
Derek J. Maetzold
Board Member
people
Alejandro Sanchez
Board Member

Unlock access to complete

Funding Insights of PreludeDx

PreludeDx has successfully raised a total of $51.65M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $5 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 7
  • Last Round Series B — $5.0M
  • First Round

    (15 Mar 2016)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2025 Amount Series B - PreludeDx Valuation

investors

Mar, 2022 Amount Series B - PreludeDx Valuation Evidity Health Capital
Jul, 2021 Amount Series B - PreludeDx Valuation GenesisCare
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in PreludeDx

PreludeDx has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include GenesisCare and Evidity Health Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Late-stage venture capital and growth equity investments are managed by Evidity Health Capital.
Founded Year Domain Location
A chain of multi-speciality clinics is operated in Australia.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by PreludeDx

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - PreludeDx

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Preludedx Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of PreludeDx

PreludeDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Raysearch laboratories, Miltel, OncoStem, Inbiomotion and POC Medical Systems, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Cloud-based radiation therapy software is developed for oncology professionals.
domain founded_year HQ Location
Telomere tests for aging detection and cellular senescence are provided.
domain founded_year HQ Location
Prognostic tests for cancer detection and recurrence risk are developed.
domain founded_year HQ Location
Biomarkers for predicting bone metastasis in cancer patients are developed.
domain founded_year HQ Location
Develops rapid tools for breast cancer detection and disease screening worldwide.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about PreludeDx

When was PreludeDx founded?

PreludeDx was founded in 2009 and raised its 1st funding round 7 years after it was founded.

Where is PreludeDx located?

PreludeDx is headquartered in Laguna Hills, United States. It is registered at Laguna Hills, California, United States.

Who is the current CEO of PreludeDx?

Daniel Forche is the current CEO of PreludeDx.

Is PreludeDx a funded company?

PreludeDx is a funded company, having raised a total of $51.65M across 7 funding rounds to date.

How many employees does PreludeDx have?

As of Dec 31, 2021, the latest employee count at PreludeDx is 33.

What does PreludeDx do?

Founded in 2009 and headquartered in Laguna Hills, United States, PreludeDx operates in the medical diagnostics sector. Risk assessment tests for early-stage breast cancer are developed and offered, with the DCISionRT product focused on ductal carcinoma in situ (DCIS) patients. Disease-associated biomarkers and proprietary algorithms are utilized to classify patients into high- and low-risk groups, while treatment predictions for cancer patients are also generated through the system.

Who are the top competitors of PreludeDx?

PreludeDx's top competitors include Raysearch laboratories, OncoStem and Biotheranostics.

What products or services does PreludeDx offer?

PreludeDx offers DCISionRT.

Who are PreludeDx's investors?

PreludeDx has 2 investors. Key investors include GenesisCare, and Evidity Health Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available